Tuberculosis

Seminars in Nuclear Medicine

Volumn 48, Issue 2, 2018, Pages 108-130

  Ankrah, Alfred O ^a,b   Glaudemans, Andor W J M ^c   Maes, Alex ^a,c,d   Van de Wiele, Christophe ^a,e   Dierckx, Rudi A J O ^b   Vorster, Mariza ^a   Sathekge, Mike M ^a  

^a STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c AZ GROENINGE   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ALFATIDE GA 68; CARBON 11; CHOLINE DERIVATIVE; FLUORINE 18; FLUORO LEVO THYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; TRACER; UNCLASSIFIED DRUG;

ABDOMINAL TUBERCULOSIS; ABDOMINAL TUBERCULOSIS LYMPHADENITIS; BRAIN ABSCESS; CARDIAC MUSCLE; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CHILDHOOD DISEASE; EXTRAPULMONARY TUBERCULOSIS; GRANULOMA; HEPATIC TUBERCULOSIS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; LUNG LESION; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIOSIS; NEUTROPHIL; OCULAR TUBERCULOSIS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PYREXIA IDIOPATHICA; REVIEW; RISK FACTOR; TUBERCULOSIS; TUBERCULOSIS BRAIN ABSCESS; TUBERCULOSIS GRANULOMA; TUBERCULOSIS SPONDYLODISCITIS; TUBERCULOUS ARTHRITIS; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS MENINGITIS; TUBERCULOUS OSTEOMYELITIS; TUBERCULOUS PERICARDITIS; TUBERCULOUS PERITONITIS; TUBERCULOUS PLEURISY; TUBERCULOUS SPONDYLITIS; UROGENITAL TUBERCULOSIS; COMPLICATION; DIAGNOSTIC IMAGING;

FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RISK FACTORS; TUBERCULOSIS;

EID: 85034439652     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2017.10.005     Document Type: Review

References (150)

1. WHO, Global tuberculosis report. Available at http://www.who.int/tb/publications/global_report/en/, 2016. (Accessed 25 May 2017)
2. Sotgiu, G., Dara, M., Centis, R., et al. Breaking the barriers: Migrants and tuberculosis. Presse Med 46 (2017), e5–e11.
3. Raviglione, M., Sulis, G., Tuberculosis 2015: Burden, challenges and strategy for control and elimination. Infect Dis Rep, 8, 2016, 6570.
4. Ankrah, A.O., van der Werf, T.S., de Vries, E.F., et al. PET/CT imaging of Mycobacterium tuberculosis infection. Clin Transl Imaging 4 (2016), 131–144.
5. Smith, I., Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 16 (2003), 463–496.
6. Hunter, R.L., Actor, J.K., Hwang, S.A., et al. Pathogenesis of post primary tuberculosis: Immunity and hypersensitivity in the development of cavities. Ann Clin Lab Sci 44 (2014), 365–387.
7. Narasimhan, P., Wood, J., Macintyre, C.R., et al. Risk factors for tuberculosis. Pulm Med, 2013, 828939.
8. Pareek, M., Greenaway, C., Noori, T., et al. The impact of migration on tuberculosis epidemiology and control in high-income countries: A review. BMC Med 14 (2016), 1–10.
9. Lönnroth, K., Mor, Z., Erkens, C., et al. Tuberculosis in migrants in low-incidence countries: Epidemiology and intervention entry points. Int J Tuberc Lung Dis 21 (2017), 624–637.
10. Cooper, A.M., Cell mediated immune responses in tuberculosis. Annu Rev Immunol 27 (2009), 393–422.
11. Pai, M., Behr, M.A., Dowdy, D., et al. Tuberculosis. Nat Rev Dis Primers, 2, 2016, 16076.
12. Schnappinger, D., Ehrt, S., A broader spectrum of tuberculosis. Nat Med 22 (2016), 1076–1077.
13. Cadena, A.M., Flynn, J.L., Fortune, S.M., The importance of first impressions: Early events in Mycobacterium tuberculosis infection influence outcome. MBio, 7, 2016 e00342-16.
14. Sharma, S.K., Mohan, A., Extrapulmonary tuberculosis. Indian J Med Res 120 (2004), 316–353.
15. Gambhir, S., Ravina, M., Rangan, K., et al. Imaging in extrapulmonary tuberculosis. Int J Infect Dis 56 (2017), 237–247.
16. Sathekge, M., Maes, A., Van de Wiele, C., FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med 43 (2013), 349–366.
17. Zar, H.J., Cornell, T.G., Nicol, M., Diagnosis of pulmonary tuberculosis in children: New advances. Expert Rev Anti Infect Ther 8 (2010), 277–288.
18. Steingart, K.R., Schiller, I., Horne, D.J., et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev(1), 2014 CD009593.
19. Woodring, J.H., Vandiviere, H.M., Fried, A.M., et al. Update: The radiographic features of pulmonary tuberculosis. AJR Am J Roentgenol 146 (1986), 497–506.
20. Jeong, Y.J., Lee, K.S., Pulmonary tuberculosis: Up-to-date imaging and management. AJR Am J Roentgenol 191 (2008), 834–844.
21. 18F-FDG PET and PET/CT. Curr Opin Pulm Med 20 (2014), 287–293.
22. Sathekge, M., Maes, A., Asseler, Y.D., et al. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals. Nucl Med Commun 33 (2012), 581–590.
23. Signore, A., Glaudemans, A.W., The molecular imaging approach to image infections and inflammation by nuclear medicine techniques. Ann Nucl Med 25 (2011), 681–700.
24. Stelzmueller, I., Huber, H., Wunn, R., et al. 18F-FDG PET/CT in the initial assessment and for follow-up in patients with tuberculosis. Clin Nucl Med 41 (2016), e187–e194.
25. Sathekge, M., Maes, A., D'Asseler, Y., et al. Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging 39 (2012), 1184–1190.
26. Ichiya, Y., Kuwabara, Y., Sasaki, M., et al. FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ann Nucl Med 10 (1996), 185–191.
27. Goo, J.M., Im, J.G., Do, K.H., et al. Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases. Radiology 216 (2000), 117–121.
28. Kim, I.J., Lee, J.S., Kim, S.J., et al. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging 35 (2008), 808–814.
29. Boyaci, H., Basyigit, I., Baris, S.A., Positron emission tomography/computed tomography in cases with tuberculosis mimicking lung cancer. Braz J Infect Dis 17 (2013), 267–269.
30. Doycheva, D., Deuter, C., Hetzel, J., et al. The use of positron emission tomography/CT in the diagnosis of tuberculosis-associated uveitis. Br J Ophthalmol 95 (2011), 1290–1294.
31. Sathekge, M.M., Maes, A., Pottel, H., et al. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J 100 (2010), 598–601.
32. Dong, A., Dong, H., Wang, Y., et al. (18)F-FDG PET/CT in differentiating acute tuberculous from idiopathic pericarditis: Preliminary study. Clin Nucl Med 38 (2013), e160–e165.
33. Martin, C., Castaigne, C., Tondeur, M., et al. Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: A prospective study. HIV Med 14 (2013), 455–462.
34. Jeong, Y.J., Paeng, J.C., Nam, H.Y., et al. (18)F-FDG positron-emission tomography/computed tomography findings of radiographic lesions suggesting old healed tuberculosis. J Korean Med Sci 29 (2014), 386–391.
35. Ghesani, N., Patrawalla, A., Lardizabal, A., et al. Increased cellular activity in thoracic lymph nodes in early human latent tuberculosis infection. Am J Respir Crit Care Med 189 (2014), 748–750.
36. Del Giudice, G., Bianco, A., Cennamo, A., et al. Lung and nodal involvement in nontuberculous mycobacterial disease: PET/CT role. Biomed Res Int, 2015, 353202.
37. Esmail, H., Lai, R., Lesosky, M., et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nat Med 22 (2016), 1090–1093.
38. Malherbe, S.T., Shenai, S., Ronacher, K., et al. Persisting PET-CT lesion activity and M. tuberculosis mRNA after pulmonary tuberculosis cure. Nat Med 2 (2016), 1094–1100.
39. Wang, S.B., Ji, Y.H., Wu, H.B., et al. PET/CT for differentiating between tuberculous peritonitis and peritoneal carcinomatosis: The parietal peritoneum. Medicine (Baltimore), 96, 2017, e5867.
40. Sun, Y., Yu, H., Ma, J., et al. The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PLoS ONE, 11, 2016 e0161764.
41. Gambhir, S., Kumar, M., Ravina, M., et al. Role of 18F-FDG PET in demonstrating disease burden in patients with tuberculous meningitis. J Neurol Sci 370 (2016), 196–200.
42. Lefebvre, N., Argemi, X., Meyer, N., et al. Clinical usefulness of 18F-FDG PET/CT for initial staging and assessment of treatment efficacy in patients with lymph node tuberculosis. Nucl Med Biol 50 (2017), 17–24.
43. Bassetti, M., Merelli, M., Di Gregorio, F., et al. Higher fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) uptake in tuberculous compared to bacterial spondylodiscitis. Skeletal Radiol 46 (2017), 777–783.
44. Demura, Y., Tsuchida, T., Uesaka, D., et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 36 (2009), 632–639.
45. Sathekge, M., Maes, A., Kgomo, M., et al. Impact of FDG PET on the management of TBC treatment. A pilot study. Nuklearmedizin 49 (2010), 35–40.
46. Coussens, A.K., Wilkinson, R.J., Nikolayevskyy, V., et al. Ethnic variation in inflammatory profile in tuberculosis. PLoS Pathog, 9, 2013, 1003468.
47. Coscolla, M., Gagneux, S., Consequences of genomic diversity in Mycobacterium tuberculosis. Semin Immunol 26 (2014), 431–444.
48. Pareek, M., Evans, J., Innes, J., et al. Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype. Thorax 68 (2013), 221–229.
49. Heysell, S.K., Thomas, T.A., Sifri, C.D., et al. 18-fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: A case series. BMC Pulm Med, 13, 2013, 14.
50. Sümbül, A.T., Sezer, A., Abali, H., et al. An old enemy not to be forgotten during PET CT scanning of cancer patients: Tuberculosis. Contemp Oncol (Pozn) 20 (2016), 188–191.
51. Chen, C., Zhu, Y.H., Qian, H.Y., et al. Pulmonary tuberculosis with false-positive 18F-fluorodeoxyglucose positron emission tomography mimicking recurrent lung cancer: A case report. Exp Ther Med 9 (2015), 159–161.
52. Akgul, A.G., Liman, S.T., Topcu, S., et al. False positive PET scan deserves attention. J BUON 19 (2014), 836–841.
53. Ruilong, Z., Daohai, X., Li, G., et al. Diagnostic value of 18F-FDG-PET/CT for the evaluation of solitary pulmonary nodules: A systematic review and meta-analysis. Nucl Med Commun 38 (2017), 67–75.
54. 18F-FDG-PET/CT in the evaluation of solitary pulmonary nodules. Eur J Radiol 84 (2015), 2032–2037.
55. Demir, Y., Polack, B.D., Karaman, C., et al. The diagnostic role of dual-phase (18)F-FDG PET/CT in the characterization of solitary pulmonary nodules. Nucl Med Commun 35 (2014), 260–267.
56. Sebro, R., Aparici, C.M., Hernandez-Pampaloni, M., FDG PET/CT evaluation of pathologically proven pulmonary lesions in an area of high endemic granulomatous disease. Ann Nucl Med 27 (2013), 400–405.
57. Vorster, M., Maes, A., Van de Wiele, C., et al. 68Ga-citrate PET/CT in Tuberculosis: A pilot study. Q J Nucl Med Mol Imaging, 2014 [Epub ahead of print].
58. Hara, T., Kosaka, N., Suzuki, T., et al. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: A positron tomography study. Chest 124 (2003), 893–901.
59. 18F-FDG. J Nucl Med 49 (2008), 186–194.
60. Kang, F., Wang, S., Tian, F., et al. Comparing the diagnostic potential of 68Ga-Alfatide II and 18F-FDG in differentiating between non-small cell lung cancer and tuberculosis. J Nucl Med 57 (2016), 672–677.
61. Pyka, T., Weirich, G., Einspieler, I., et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med 57 (2016), 367–371.
62. Belton, M., Brilha, S., Manavaki, R., et al. Hypoxia and tissue destruction in pulmonary TB. Thorax 71 (2016), 1145–1153.
63. D'Souza, M.M., Sharma, R., Jaimini, A., et al. Metabolic assessment of intracranial tuberculomas using 11C-methionine and 18F-FDG PET/CT. Nucl Med Commun 33 (2012), 408–414.
64. Soussan, M., Brillet, P.Y., Mekinian, A., et al. Patterns of pulmonary tuberculosis on FDG-PET/CT. Eur J Radiol 81 (2012), 2872–2876.
65. Geng, E., Kreiswirth, B., Burzynski, J., et al. Clinical and radiographic correlates of primary and reactivation tuberculosis: A molecular epidemiology study. JAMA 293 (2005), 2740–2745.
66. Barry, C.E., Boshoff, H.I., Dartois, V., et al. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 7 (2009), 845–855.
67. Lin, P.L., Maiello, P., Gideon, H.P., et al. PET CT identifies reactivation risk in cynomolgus macaques with latent M. tuberculosis. PLoS Pathog, 12, 2016, 1005739.
68. Horsburgh, C.R., Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 350 (2004), 2060–2067.
69. Horsburgh, C.R., O'Donnell, M., Chamblee, S., et al. Revisiting rates of reactivation tuberculosis: A population-based approach. Am J Respir Crit Care Med 182 (2010), 420–425.
70. Thomas, A., Gopi, P.G., Santha, T., et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis 9 (2005), 556–561.
71. Diel, R., Loddenkemper, R., Nienhaus, A., Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: A meta-analysis. Chest 142 (2012), 63–75.
72. Ryu, Y.J., Koh, W.J., Daley, C.L., Diagnosis and treatment of nontuberculous mycobacterial lung disease: Clinicians' perspectives. Tuberc Respir Dis (Seoul) 79 (2016), 74–84.
73. Vorster, M., Maes, A., Van de Wiele, C., et al. Gallium-68 PET: A powerful generator-based alternative to infection and inflammation imaging. Semin Nucl Med 46 (2016), 436–447.
74. Vorster, M., Maes, A., Jacobs, A., et al. Evaluating the possible role of 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions. Ann Nucl Med 28 (2014), 523–530.
75. Vorster, M., Stoltz, A., Jacobs, A.G., et al. Imaging of pulmonary tuberculosis with 18F-fluoro-deoxy-glucose and 18F-ethylcholine. Open Nucl Med J 6 (2014), 17–21.
76. Ankrah, A.O., Glaudemans, A.W., Sathekge, M.M., et al. Imaging latent tuberculosis infection with radiolabeled nitroimidazoles. Clin Transl Imaging 4 (2016), 157–159.
77. Lenaerts, A., Barry, C.E., Dartois, V., Heterogeneity in tuberculosis pathology, microenvironments and therapeutic response. Immunol Rev 264 (2015), 288–307.
78. Salvador, F., Los-Arcos, I., Sánchez-Montalvá, A., et al. Epidemiology and diagnosis of tuberculous lymphadenitis in a tuberculosis low-burden country. Medicine (Baltimore), 4, 2015, e509.
79. Enomoto, K., Hoshida, Y., Hamada, K., et al. F-18 FDG PET imaging of cervical tuberculous lymphadenitis. Clin Nucl Med 32 (2007), 474–475.
80. Karunanithi, S., Kumar, G., Sharma, P., et al. Potential role of (18)F-2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography imaging in patients presenting with generalized lymphadenopathy. Indian J Nucl Med 1 (2015), 31–38.
81. Vorster, M.J., Allwood, B.W., Diacon, A.H., et al. Tuberculous pleural effusions: Advances and controversies. J Thorac Dis 7 (2015), 981–991.
82. Tian, G., Xiao, Y., Chen, B., et al. Multi-site abdominal tuberculosis mimics malignancy on 18F-FDG PET/CT: Report of three cases. World J Gastroenterol 16 (2010), 4237–4242.
83. Obama, K., Kanai, M., Taki, Y., et al. Tuberculous lymphadenitis as a cause of obstructive jaundice: Report of a case. Surg Today 33 (2003), 229–231.
84. 18F-FDG PET/CT in the evaluation of peritoneal thickening of undetermined origin. Medicine (Baltimore), 95, 2016, e3023.
85. Zhang, M., Jiang, X., Zhang, M., et al. The role of 18F-FDG PET/CT in the evaluation of ascites of undetermined origin. J Nucl Med 50 (2009), 506–512.
86. Wang, X., Shi, X., Yi, C., et al. Hepatic tuberculosis mimics metastasis revealed by 18F-FDG PET/CT. Clin Nucl Med 39 (2014), e325–e327.
87. Puranik, A.D., Purandare, N.C., Sridhar, E., et al. Rare solitary focal tuberculous involvement of liver masquerading as hepatic metastasis on FDG PET/CT in a case of fibular round cell tumor. Indian J Nucl Med 30 (2015), 65–67.
88. Wong, S.S., Yuen, H.Y., Ahuja, A.T., Hepatic tuberculosis: A rare cause of fluorodeoxyglucose hepatic superscan with background suppression on positron emission tomography. Singapore Med J 55 (2014), e101–e103.
89. Jeong, Y.J., Sohn, M.H., Lim, S.T., et al. “Hot liver” on 18F-FDG PET/CT imaging in a patient with hepatosplenic tuberculosis. Eur J Nucl Med Mol Imaging 8 (2010), 1618–1619.
90. Roudaut, N., Malecot, J.M., Dupont, E., et al. Adrenal tuberculosis revealed by FDG PET. Clin Nucl Med 33 (2008), 821–823.
91. Sanabe, N., Ikematsu, Y., Nishiwaki, Y., et al. Pancreatic tuberculosis. J Hepatobiliary Pancreat Surg 9 (2002), 515–518.
92. Subramanyam, P., Palaniswamy, S.S., Dual time point (18)F-FDG PET/CT imaging identifies bilateral renal tuberculosis in an immunocompromised patient with an unknown primary malignancy. Infect Chemother 47 (2015), 117–119.
93. Dong, A., Wang, Y., Gong, J., et al. FDG PET/CT findings of common bile duct tuberculosis. Clin Nucl Med 39 (2014), 67–70.
94. Wang, H.Y., Lin, W.Y., Jejunal tuberculosis: Incidental finding on an FDG-PET scan. Kaohsiung J Med Sci 22 (2006), 34–38.
95. Murray, M.R., Schroeder, G.D., Hsu, W.K., Granulomatous vertebral osteomyelitis: An update. J Am Acad Orthop Surg 23 (2015), 529–538.
96. Kim, K., Kim, S.J., Kim, I.J., et al. Diffuse increased splenic F-18 fluorodeoxyglucose uptake may be an indirect sign of acute pyogenic cause rather than tuberculous in patients with infectious spondylitis. Nucl Med Commun 32 (2011), 1155–1161.
97. Fuster, D., Tomás, X., Granados, U., et al. A prospective comparison of whole-body (18)F-FDG PET/CT and MRI of the spine in the diagnosis of haematogenous spondylodiscitis: Response to comments by Soussan. Eur J Nucl Med Mol Imaging 42 (2015), 356–357.
98. Gratz, S., Dörner, J., Fischer, U., et al. 18F-FDG hybrid PET in patients with suspected spondylitis. Eur J Nucl Med Mol Imaging 29 (2002), 516–524.
99. Wang, J.H., Chi, C.Y., Lin, K.H., et al. Tuberculous arthritis—Unexpected extrapulmonary tuberculosis detected by FDG PET/CT. Clin Nucl Med 38 (2013), e93–e94.
100. Makis, W., Abikhzer, G., Stern, J., Tuberculous synovitis of the hip joint diagnosed by FDG PET-CT. Clin Nucl Med 34 (2009), 431–432.
101. Cho, Y.S., Chung, D.R., Lee, E.J., et al. 18F-FDG PET/CT in a case of multifocal skeletal tuberculosis without pulmonary disease and potential role for monitoring treatment response. Clin Nucl Med 39 (2014), 980–983.
102. Ntsekhe, M., Mayosi, B.M., Tuberculous pericarditis with and without HIV. Heart Fail Rev 18 (2013), 367–373.
103. Lawal, I., Sathekge, M., F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection. Br Med Bull 120 (2016), 55–74.
104. Testempassi, E., Kubota, K., Morooka, M., et al. Constrictive tuberculous pericarditis diagnosed using 18F-fluorodeoxyglucose positron emission tomography: A report of two cases. Ann Nucl Med 24 (2010), 421–425.
105. Braquet, P., Baptista, G., Ilonca, D.A., et al. FDG-PET in a myocardial tuberculoma. Age Ageing 44 (2015), 173–174.
106. Sperry, B.W., Oldan, J.D., Hsich, E.M., et al. Infectious myocarditis on FDG-PET imaging mimicking sarcoidosis. J Nucl Cardiol 22 (2015), 840–844.
107. Kang, K., Lim, I., Roh, J.K., Positron emission tomographic findings in a tuberculous brain abscess. Ann Nucl Med 21 (2007), 303–306.
108. Sharma, J.B., Karmakar, D., Kumar, R., et al. Comparison of PET/CT with other imaging modalities in women with genital tuberculosis. Int J Gynaecol Obstet 118 (2012), 123–128.
109. Lee, G., Lee, J.H., Park, S.G., F-18 FDG PET/CT imaging of solitary genital tuberculosis mimicking recurrent lymphoma. Clin Nucl Med 36 (2011), 315–316.
110. Mehta, S., Observed patterns of systemic disease on PET/CT scan in patients with presumed ocular tuberculosis: Findings and hypotheses. Ocul Immunol Inflamm 20 (2016), 1–3.
111. Chen, X., Lu, H., Gao, Y., FDG PET/CT showing erythema nodosum associated with tuberculous lymphadenitis. Clin Nucl Med 38 (2013), 992–993.
112. Garg, G., Tripathi, M., D'Souza, M., et al. Demonstration of a tubercular fistula-in-ano on F-18 FDG PET/CT. Clin Nucl Med 4 (2010), 300–302.
113. Bakheet, S.M., Powe, J., Kandil, A., et al. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 2 (2000), 100–103.
114. Das, C.J., Kumar, R., Balakrishnan, V.B., et al. Disseminated tuberculosis masquerading as metastatic breast carcinoma on PET-CT. Clin Nucl Med 33 (2008), 359–361.
115. Liu, B., Dong, L., Wang, X., et al. Tuberculosis mimicking metastases by malignancy in FDG PET/CT. QJM 110 (2017), 173–174.
116. Nordin, A.J., Rossetti, C., Rahim, N.A., Disseminated tuberculosis infection: A “super” 18F-FDG PET/CT appearance. Eur J Nucl Med Mol Imaging, 36, 2009, 882.
117. Ankrah, A.O., Glaudemans, A.W., Klein, H.C., et al. The role of nuclear medicine in the staging and management of human immune deficiency virus infection and associated diseases. Nucl Med Mol Imaging 51 (2017), 127–139.
118. Sathekge, M., Maes, A., Kgomo, M., et al. FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: Implications for cancer staging. Q J Nucl Med Mol Imaging 54 (2010), 698–703.
119. Mhlanga, J.C., Durand, D., Tsai, H.L., et al. Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Nucl Med Mol Imaging 41 (2014), 596–604.
120. Sathekge, M., Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry. Eur J Nucl Med Mol Imaging 41 (2014), 593–595.
121. Cha, J., Lee, H.Y., Lee, K.S., et al. Radiological findings of extensively drug-resistant pulmonary tuberculosis in non-AIDS adults: Comparisons with findings of multidrug-resistant and drug-sensitive tuberculosis. Korean J Radiol 10 (2009), 207–216.
122. Yeom, J.A., Jeong, Y.J., Jeon, D., et al. Imaging findings of primary multidrug-resistant tuberculosis: A comparison with findings of drug-sensitive tuberculosis. J Comput Assist Tomogr 33 (2009), 956–960.
123. Chen, R.Y., Dodd, L.E., Lee, M., et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med, 6, 2014, 265ra166.
124. Mukherjee, T., Boshoff, H., Nitroimidazoles for the treatment of TB: Past, present and future. Future Med Chem 3 (2011), 1427–1454.
125. Kour, G., Singh, P.P., Bhagat, A., et al. Biopharmaceutic parameters, pharmacokinetics, transport and CYP-mediated drug interactions of IIIM-017: A novel nitroimidazooxazole analogue with anti-tuberculosis activity. Eur J Pharm Sci 106 (2017), 71–78.
126. Mahon, R.N., Hafner, R., Applying precision medicine and immunotherapy advances from oncology to host-directed therapies for infectious diseases. Front Immunol, 8, 2017, 688.
127. Ramakrishnan, L., Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12 (2012), 352–366.
128. Ehlers, S., Schaible, U.E., The granuloma in tuberculosis: Dynamics of a host-pathogen collusion. Front Immunol, 3, 2013, 411.
129. Mattila, J.T., Beaino, W., Maiello, P., et al. Positron emission tomography imaging of macaques with tuberculosis identifies temporal changes in granuloma glucose metabolism and integrin α4β1-expressing immune cells. J Immunol 199 (2017), 806–815.
130. Ndlovu, H., Marakalala, M.J., Granulomas and inflammation: Host-directed therapies for tuberculosis. Front Immunol, 7, 2016, 434.
131. Sica, A., Erreni, M., Allavena, P., et al. Macrophage polarization in pathology. Cell Mol Life Sci 72 (2015), 4111–4126.
132. Weissleder, R., Nahrendorf, M., Pittet, M.J., Imaging macrophages with nanoparticles. Nat Mater 13 (2014), 125–138.
133. Tarkin, J.M., Joshi, F.R., Evans, N.R., Detection of atherosclerotic inflammation by 68Ga-DOTATATE PET compared to [18F]FDG PET. Imaging J Am Coll Cardiol 69 (2017), 1774–1791.
134. Locke, L.W., Chordia, M.D., Zhang, Y., et al. A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64Cu. J Nucl Med 50 (2009), 790–797.
135. Lyadova, I.V., Neutrophils in tuberculosis: Heterogeneity shapes the way?. Mediators Inflamm, 2017, 8619307.
136. Eum, S.Y., Kong, J.H., Hong, M.S., et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137 (2010), 122–128.
137. Dorhoi, A., Kaufmann, S.H., Pathology and immune reactivity: Understanding multidimensionality in pulmonary tuberculosis. Semin Immunopathol 38 (2016), 153–166.
138. Kaplan, G., Post, F.A., Moreira, A.L., Mycobacterium tuberculosis growth at the cavity surface: A microenvironment with failed immunity. Infect Immun 71 (2003), 7099–7108.
139. Yii, A.C., Koh, M.S., Lapperre, T.S., et al. The emergence of Aspergillus species in chronic respiratory disease. Front Biosci (Schol Ed) 9 (2017), 127–138.
140. Ankrah, A.O., Klein, H.C., Span, L.F., et al. The role of PET in monitoring therapy in fungal infections. Curr Pharm Des, 2017 in press.
141. Tavaré, R., McCracken, M.N., Zettlitz, K.A., et al. Immuno-PET of murine T cell reconstitution postadoptive stem cell transplantation using anti-CD4 and anti-CD8 cys-diabodies. J Nucl Med 56 (2015), 1258–1264.
142. Coello, C., Fisk, M., Mohan, D., et al. Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation. EJNMMI Res, 7, 2017, 47.
143. Qualls, J.E., Murray, P.J., Immunometabolism within the tuberculosis granuloma: Amino acids, hypoxia, and cellular respiration. Semin Immunopathol 38 (2016), 139–152.
144. Tek Chand, K., Chennu, K.K., Amancharla Yadagiri, L., et al. Utility of 18 F-FDG PET/CT scan to diagnose the etiology of fever of unknown origin in patients on dialysis. Hemodial Int 2 (2017), 224–231.
145. Castaigne, C., Tondeur, M., de Wit, S., et al. Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: A retrospective study. Nucl Med Commun 30 (2009), 41–47.
146. Pelletier-Galarneau, M., Martineau, P., Zuckier, L.S., et al. 18F-FDG-PET/CT imaging of thoracic and extrathoracic tuberculosis in children. Semin Nucl Med 47 (2017), 304–318.
147. Jadvar, H., Colletti, P.M., Competitive advantage of PET/MR. Eur J Radiol 83 (2014), 84–94.
148. Zhang, Z., Ordonez, A.A., Smith-Jones, P., et al. The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography. PLoS ONE, 12, 2017 e0170871.
149. Rundell, S.R., Wagar, Z.L., Meints, L.M., et al. Deoxyfluoro-d-trehalose (FDTre) analogues as potential PET probes for imaging mycobacterial infection. Org Biomol Chem 14 (2016), 8598–8609.
150. WHO, The End TB Strategy—World Health Organization. Available at http://www.who.int/tb/strategy/end-tb/en/, 2017. (Accessed 29 May 2017)